Erlotinib-induced hepatotoxicity-clinical presentation and successful management: A case report

Journal of Clinical and Experimental Hepatology

Volumn 1, Issue 1, 2011, Pages 38-40

  Arora, Anil K ^a  

^a SIR GANGA RAM HOSPITAL   (India)

Author keywords

Drug induced liver injury; Epidermal growth factor receptor hepatotoxicity; Tyrosine kinase inhibitor

Indexed keywords

BILIRUBIN; ERLOTINIB; LOPERAMIDE; METRONIDAZOLE; OFLOXACIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; ARTICLE; CASE REPORT; CLINICAL FEATURE; CLINICAL PRACTICE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; DRUG ERUPTION; DRUG INDICATION; DRUG USE; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; MORTALITY; NONALCOHOLIC FATTY LIVER; PANCREAS CANCER; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; SIDE EFFECT; TOXIC HEPATITIS; VIRUS HEPATITIS;

EID: 83455212079     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/S0973-6883(11)60112-6     Document Type: Article

References (15)

1. Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010, 52:2065-2076.
2. Kumar R, Shalimar, Bhatia V, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology 2010, 51:1665-1674.
3. Gluud C Acute, serious drug-induced liver injury. J Hepatol 2002, 97:675-677.
4. Hidalgo M, Siu LL, Nemunitis J, et al. Phase I and pharmacologic study of osi-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267-3279.
5. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
6. Pellegrinotti M, Fimognari FL, Franco A, Repetto L, Pastorelli R Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. Ann Pharmacother 2009, 43:542-545.
7. Ramanarayanan J, Scarpace SL Acute drug induced hepatitis due to erlotinib. JOP 2007, 8:39-43.
8. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005, 10:461-466.
9. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006, 24:3069-3074.
10. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005, 23:6657-6663.
11. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol 2007, 25:1960-1966.
12. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naïve patients = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:760-766.
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123.
14. Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007, 5:917-920.
15. Pellegrinotti M, Fimognari FL, Franco A, et al. Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. Ann Pharmacother 2009, 43:542.